酷派集團(02369.HK)擬折讓約17.3%增發8億股 淨籌1.71億港元
格隆匯10月7日丨酷派集團(02369.HK)公告,於2019年10月7日,公司已與認購人訂立認購協議,據此,公司已有條件同意配發及發行,而認購人已有條件同意認購8億股認購股份,認購價為每股認購股份0.215港元。較公司10月4日收市價每股0.26港元折讓約17.3%.
認購股份佔經配發及發行認購股份擴大公司已發行股約13.71%。認購股份將根據一般授權獲配發及發行。認購事項所得款項總額將為1.72億港元。認購事項所得款項淨額(經扣除認購事項產生的開支後)估計將約為1.71億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.